Dedicated to the
Health and Welfare of All Cats
A A A
Font Size
hero-education

Cat Health News Blog

A resource for dedicated cat supporters

Since its start in 2007, Cat Health News has featured the latest information on feline health. The bi-weekly blog is a mix of the most current published research from Winn-funded research and other sources. There are over 875 blog post items and more than 1,000 subscribers through the RSS feed.


icon-blogWinn-funded research is specifically noted by the small green cat.

  • Treatment of anemia in cats with chronic kidney disease

    Jan 29, 2013
    Final report: Winn grant W11-035
    Vapniarsky N, Lame M, McDonnel S and Murphy B. A lentiviral gene therapy strategy for the in vitro production of feline erythropoietin. PLoS ONE. 2012; 7: e45099. [free, full text] 
     
    A common problem in domestic cats with chronic renal failure (CRF) is non-regenerative anemia. Currently, the administration of recombinant human erythropoietin (rHuEPO) frequently only improves anemia temporarily due to antibody development. Antibodies can develop within the first few months of rHuEPO administration. A clinically significant reaction has been reported in 20-70% of feline patients receiving rHuEPO. Adverse reactions reported with the use of rHUEPO in cats are refractory anemia, systemic hypertension, polycythemia, seizures, vomiting, iron deficiency, injection discomfort, cellulitis, cutaneous or mucocutaneous reactions, and arthralgia. Several therapeutic strategies utilizing species-specific recombinant EPO have attempted to address this issue of immunogenicity in cats.

    In this study, the researchers wanted to investigate a possible gene delivery system for treatment of CRF-associated non-regenerative anemia that would have limited or no secondary immunogenicity, have stable and native transgene expression, and the ability to transduce both dividing and non-dividing cells. They looked at the ability of replication-incompetent lentiviral vectors to fulfill this list of requirements. They established an in vitro study system where feline erythropoietin cDNA was cloned from feline renal tissue and utilized in construction of a replication-defective lentiviral vector. The recombinant feline erythropoietin sequence was confirmed by subsequent sequencing. The results demonstrated the feasibility of this type of in vitro delivery system for the production of biologically active feline erythropoietin. In the future, cats with anemia due to CRF may benefit from a lentiviral gene therapy system. [VT]

    See also: Chalhoub S, Langston CE and Farrelly J. The use of darbepoetin to stimulate erythropoiesis in anemia of chronic kidney disease in cats: 25 cases. J Vet Intern Med. 2012; 26: 363-9.

    erythropoietin chronic kidney disease anemia

    More on cat health:

    Winn Feline Foundation Library
    Find us on Facebook
    Follow us on Twitter
    Pin with us on Pinterest
    Join us on Google+

 

Archives

2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007